An Open-label Phase I/II Clinical Trial of PT-112 Injection Alone in the Treatment of Patients With Advanced Solid Tumors and Advanced Hepatocellular Carcinoma

Trial Profile

An Open-label Phase I/II Clinical Trial of PT-112 Injection Alone in the Treatment of Patients With Advanced Solid Tumors and Advanced Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs PT 112 (Primary)
  • Indications Liver cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors SciClone Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 22 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top